Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
Date:4/28/2011

e U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) on the design and planned analysis of the ASPIRE trial. Carfilzomib is also being evaluated in the Phase 3 European FOCUS trial, which is designed to support a European registrational filing.  Carfilzomib is also being evaluated in a broad investigator sponsored trial program including first-line multiple myeloma, combination studies, lymphoma and other malignancies.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In Europe, it is estimated that more than 60,000 people are living with multiple myeloma and approximately 21,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
2. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
7. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
10. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
11. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Decision Resources Group,s ... about by the Affordable Care Act (ACA), ... of pharmaceutical therapies. The ACA altered how ... new regulations and expanded access via government-supported ... health exchanges—state-based marketplaces set up by states ...
(Date:7/31/2014)... Calif. , July 31, 2014 Touro ... it has been selected as the recipient of a ... which will allow the University to increase research and ... about creating state-of-the-art technology for the study of health ... enhance the diverse needs and interests of our students," ...
(Date:7/31/2014)... For its innovative modular Biomedical Research building ... Scientific has earned a Modular Building Institute (MBI) 2014 ... 30 categories, MBI,s contest is the commercial modular industry,s ... manufacturers, dealers, and product and service providers. ... of our team," said Dan Palmer , President ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... DIEGO, Aug. 8, 2011 HUYA Bioscience International, a ... strategic partnership with the Shanghai Jiao Tong University School ... assist King,s Lab in accelerating the development of their ... provides HUYA with access to and first review of ...
... Wis., Aug. 8, 2011 Eurofins Optimed Clinical ... and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical ... announce a joint partnership agreement.  This partnership leverages ... on integrated clinical services to engage pharmaceutical clients ...
Cached Medicine Technology:HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 2HUYA Bioscience International and Shanghai Jiao Tong University King's Lab Form Alliance 3Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research 2
(Date:7/31/2014)... 31, 2014 Women in the Los ... of their financial future. The Independent Woman , ... registration for 6 upcoming Los Angeles area events. ... and with input from Kim Kiyosaki, a successful investor, ... Time) who is passionate about women’s financial education. , ...
(Date:7/31/2014)... The prevalence of heroin use has been rising steadily ... National Survey on Drug Use and Health, the number ... between 2007 (373,000) and 2012 (669,000). Emerging evidence suggests ... users who transition from oral and/or intranasal PO use ... regular opioid use, and ultimately, heroin injection. This ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... experiences, are a source of drinking problems among U.S. National ... Setbacks such as job loss, divorce and financial problems -- ... as 13 percent of vets turn to drink, researchers found. ... effect on mental health in the short term, but what ...
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
Breaking Medicine News(10 mins):Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2
... has shown that too much heat can decrease sperm count, and ... the Bourn Hall Clinic in Cambridgeshire have suggested that soaking up ... for fathering a child. ,Many couples believe that a ... loosen up fully. ,However, sperm takes eight weeks ...
... of an estimated one in 20,000 newborns are shocked to ... a progressive and crippling genetic disorder. Although doctors know ... are available, many children are not diagnosed until they are ... have type 1 myotonic dystrophy (DM1) a common form ...
... pet food, then tooth paste and now fish. There just seems ... ,Only two days ago the US put on hold ... its finding on whether it contains diethylene glycol, a chemical commonly ... is warning that packages of fish imported from China into the ...
... pay for badly needed restorations, are reaching out to the ... bird-watching lectures, Sunday jazz concerts, brunches with star chefs, Halloween ... ,The cemetery tourism fever is catching on. ... Titanic made many gasp for breath. It looked as if ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... has found that smokers who have a say in how ... and are more successful. ,The study, which ... of human motivation, was conducted by a team of researchers ... ,The crux of Self-Determination Theory is that a ...
Cached Medicine News:Health News:Researcher Studying Disease That Cripples Newborns 2Health News:US Consumers Warned Against Toxic Chinese Fish 2Health News:Cemetery Tourism, the New Catchword in US 2Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Smokers Who Have a Say in How They Quit More Likely to Kick the Habit 2
... Offering a unique, empowering alternative to ... industry for years, MMD's PalmScan AP2000 is ... and Pachymeter combination unit on the market ... ounces and is able to perform multiple ...
... is an accurate, reliable, portable, and ... It works off of a dual-rechargeable ... the device a breeze. The large, ... operating and viewing results simple. Built ...
The Cordis ANGIOGUARD Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: